Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 52-Week High - What's Next?

Key Points

• Kiniksa Pharmaceuticals International (NASDAQ:KNSA) reached a new 52-week high at $34.73, closing at $32.83 with a trading volume of 16,549 shares.
• Recent analyst upgrades include a move from "buy" to "strong-buy" by Wall Street Zen, with a consensus rating of "Buy" and an average price target of $41.17.
• The company's latest earnings report showed a profit of $0.23 per share, exceeding estimates, alongside a revenue of $156.80 million for the quarter.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report)'s share price hit a new 52-week high on Monday . The company traded as high as $34.73 and last traded at $32.83, with a volume of 16549 shares. The stock had previously closed at $31.98.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of recent analyst reports. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Finally, Wells Fargo & Company increased their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $41.17.

Kiniksa Pharmaceuticals International Trading Up 1.5%

The firm has a market capitalization of $2.37 billion, a PE ratio of 811.63 and a beta of 0.14. The firm has a 50-day moving average of $28.38 and a two-hundred day moving average of $24.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Barry D. Quart sold 12,336 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $30.39, for a total value of $374,891.04. Following the completion of the sale, the director directly owned 12,546 shares in the company, valued at approximately $381,272.94. This represents a 49.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Eben Tessari sold 18,900 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $28.72, for a total value of $542,808.00. Following the completion of the sale, the chief operating officer owned 49,163 shares of the company's stock, valued at approximately $1,411,961.36. This represents a 27.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 314,709 shares of company stock valued at $9,013,851 in the last 90 days. 53.48% of the stock is currently owned by company insiders.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently modified their holdings of the business. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock valued at $27,000 after acquiring an additional 568 shares in the last quarter. US Bancorp DE acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at about $33,000. Asset Management One Co. Ltd. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at about $41,000. Wealthquest Corp acquired a new stake in shares of Kiniksa Pharmaceuticals International during the first quarter valued at about $42,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter worth about $61,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.